Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

3.125 +0.075 (+2.46%)
Streaming Delayed Price Updated: 11:20 AM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 259,958
Open 3.060
Bid (Size) 3.120 (1,500)
Ask (Size) 3.130 (2,600)
Prev. Close 3.050
Today's Range 3.010 - 3.135
52wk Range 2.740 - 8.590
Shares Outstanding 93,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Myriad Genetics and Moderna Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders continued to secure prof... 
Via StockStory
News headline image
1 Small-Cap Stock with Promising Prospects and 2 That Underwhelm
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
-49.1%
-49.1%
1 Month
-42.7%
-42.7%
3 Month
-18.8%
-18.8%
6 Month
-28.7%
-28.7%
1 Year
-46.9%
-46.9%

More News

Read More
News headline image
Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks
Via StockStory
Topics Artificial Intelligence
Myriad Genetics (NASDAQ:MYGN) Plunges 26% After Fiscal Q2 Revenue and EPS Miss, Slashes Full-Year Guidance ↗
Via Chartmill
News headline image
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
News headline image
3 Healthcare Stocks with Open Questions
Via StockStory
News headline image
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Myriad Genetics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Artificial Intelligence Earnings
Top movers in Friday's session ↗
Via Chartmill
News headline image
Why Myriad Genetics (MYGN) Shares Are Falling Today
Via StockStory
Topics Artificial Intelligence
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks That Fall Short
Via StockStory
News headline image
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
Via StockStory
News headline image
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Via StockStory

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?
Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
What exchange does Myriad Genetics, Inc. - Common Stock trade on?
Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
What is the current price of Myriad Genetics, Inc. - Common Stock?
The current price of Myriad Genetics, Inc. - Common Stock is 3.125
When was Myriad Genetics, Inc. - Common Stock last traded?
The last trade of Myriad Genetics, Inc. - Common Stock was at 08/25/26 11:20 AM ET
What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
The market capitalization of Myriad Genetics, Inc. - Common Stock is 292.19M
How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
Myriad Genetics, Inc. - Common Stock has 292M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.